Naloxone prolongs the survival time of mice treated with neuroblastoma.
Naloxone prolongs the survival time of mice treated with neuroblastoma.
复制标题
纳洛酮可延长接受神经母细胞瘤治疗的小鼠的存活时间。
DOI：
10.1016/0024-3205(81)90686-x
复制
发表时间：
1981
期刊：
影响因子：
6.1
通讯作者：
McLaughlin,PJ
中科院分区：
文献类型：
--
作者：
Zagon,IS;McLaughlin,PJ
研究了纳洛酮对小鼠神经母细胞瘤肿瘤生长和生存时间的影响。每日皮下注射在肿瘤细胞接种前2周（预处理组）或肿瘤移植后1周（后处理组）开始注射5、10、15或20 mg/kg纳洛酮。使用从A/Jax小鼠C1300神经母细胞瘤克隆的S20 Y细胞系，每只动物接种106个细胞。盐水-肿瘤和纳洛酮后处理组中的所有小鼠在肿瘤细胞接种后3周内发生肿瘤。在纳洛酮预处理组中，暴露于20 mg/kg的12只小鼠中有4只、暴露于15 mg/kg的12只小鼠中有2只和暴露于10 mg/kg的12只小鼠中有1只在接种后91天内未发生肿瘤。20 mg/kg纳洛酮预处理组中的3只动物在肿瘤细胞接种后43 - 63天发生肿瘤。纳洛酮给药动物的肿瘤尺寸通常减小，但未发现肿瘤大小变化幅度的剂量-反应关系。在死亡时，对照组和纳洛酮暴露组小鼠的肿瘤大小相似。一般来说，接受纳洛酮的荷瘤小鼠比盐水肿瘤对照组活得更长，接受更高药物剂量的动物存活时间最长。与对照组27天的平均存活时间相比，纳洛酮预处理组的存活时间增加了25- 61%，而纳洛酮后处理组显示出增加了20- 40%。所有暴露于纳洛酮的小鼠的中位死亡日延长了21- 75%，发生在盐水肿瘤对照组28天中位值后6-21天。这些结果表明，纳洛酮，一种非成瘾性化合物，是一种有效的药物在调节肿瘤。
The effect of naloxone on tumor growth and survival time was studied in mice with neuroblastoma tumors. Daily s.c. injections of either 5, 10, 15, or 20 mg/kg naloxone were initiated either 2 weeks prior to tumor cell inoculations (pre-treated groups) or one week after tumor transplantation (post-treated groups). The S20Y cell line, cloned from A/Jax murine C1300 neuroblastoma, was utilized and each animal was inoculated with 106cells. All mice in the saline- tumor and naloxone post-treated groups, developed tumors within 3 weeks after tumor cell inoculation. In the naloxone pre-treated groups, 4 of 12 mice exposed to 20 mg/kg, 2 of 12 mice exposed to 15 mg/kg, and 1 of 12 mice exposed to 10 mg/kg, did not develop tumors within the 91-day post-inoculation period. Three animals in the 20 mg/kg naloxone pre-treated group developed tumors between 43 and 63 days after tumor cell inoculation. Tumor dimensions were often reduced in naloxone-treated animals but a dose-response relationship was not found in regard to the magnitude of alterations in tumor size. At the time of death, tumor sizes of control and naloxone-exposed mice were similar. In general, tumor-bearing mice receiving naloxone lived longer than saline-tumor controls, with animals receiving higher drug dosages surviving for the longest time. In contrast to a mean survival time of 27 days for controls, naloxone pre-treated groups had increases in survival times of 25–61%, whereas naloxone post- treated groups exhibited increases of 20–40%. The median day of death for all mice exposed to naloxone was prolonged by 21–75%, occuring 6–21 days after the 28-day median for saline-tumor controls. These results suggest that naloxone, a non-addictive compound, is an effective agent in modulating neoplasia.